K. Wing, Y. Onishi, and P. Prieto-martin, CTLA-4 control over Foxp3+ regulatory T cell function, Science, vol.322, pp.271-275, 2008.

A. R. Kendal, Y. Chen, and F. S. Regateiro, Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance, J Exp Med, vol.208, pp.2043-2053, 2011.

Y. Akiyama, N. Shirasugi, and N. Uchida, B7/CTLA4 pathway is essential for generating regulatory cells after intratracheal delivery of alloantigen in mice, Transplantation, vol.74, pp.732-738, 2002.

R. J. Greenwald, V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe, CTLA-4 regulates induction of anergy in vivo, Immunity, vol.14, pp.145-155, 2001.

S. Issazadeh, M. Zhang, M. H. Sayegh, and S. J. Khoury, Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model, J Immunol, vol.162, pp.761-765, 1999.

V. L. Perez, L. Van-parijs, A. Biuckians, X. X. Zheng, T. B. Strom et al., Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement, Immunity, vol.6, pp.411-417, 1997.

K. S. Peggs, S. A. Quezada, C. A. Chambers, A. J. Korman, and J. P. Allison, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, J Exp Med, vol.206, pp.1717-1725, 2009.

T. Zhang, S. Fresnay, and E. Welty, Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner, Am J Transplant, vol.11, pp.1599-1609, 2011.

T. G. Markees, N. E. Phillips, and E. J. Gordon, Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferongamma, and CTLA4, J Clin Invest, vol.101, pp.2446-2455, 1998.

X. X. Zheng, T. G. Markees, and W. W. Hancock, CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment, J Immunol, vol.162, pp.4983-4990, 1999.

B. T. Fife, M. D. Griffin, A. K. Abbas, R. M. Locksley, and J. A. Bluestone, Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist, J Clin Invest, vol.116, pp.2252-2261, 2006.

M. J. Ansari and M. H. Sayegh, Costimulation couture: a designer approach to regulating autoimmunity, J Clin Invest, vol.116, pp.2080-2083, 2006.

P. Waterhouse, J. M. Penninger, and E. Timms, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, vol.270, pp.985-988, 1995.

G. Q. Phan, J. C. Yang, and R. M. Sherry, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc Natl Acad Sci, vol.100, pp.8372-8377, 2003.

F. Lühder, P. Höglund, J. P. Allison, C. Benoist, and D. Mathis, Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes, J Exp Med, vol.187, pp.427-432, 1998.

P. J. Perrin, J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke, CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis, J Immunol, vol.157, pp.1333-1336, 1996.

M. L. Alegre, K. A. Frauwirth, and C. B. Thompson, T-cell regulation by CD28 and CTLA-4, Nat Rev Immunol, vol.1, pp.220-228, 2001.

J. M. Kremer, R. Westhovens, and M. Leon, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig, N Engl J Med, vol.349, pp.1907-1915, 2003.

F. Vincenti, C. Larsen, and A. Durrbach, Costimulation blockade with belatacept in renal transplantation, N Engl J Med, vol.353, pp.770-781, 2005.

F. Vincenti, A. Dritselis, P. Kirkpatrick, and . Belatacept, Nat Rev Drug Discov, vol.10, pp.655-656, 2011.

N. Poirier, G. Blancho, and B. Vanhove, Alternatives to calcineurin inhibition in renal transplantation: Belatacept, the first co-stimulation blocker, Immunotherapy, vol.2, pp.625-636, 2010.

A. D. Kirk, D. K. Tadaki, and A. Celniker, Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates, Transplantation, vol.72, pp.377-384, 2001.

K. G. Haanstra, J. Ringers, and E. A. Sick, Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates, Transplantation, vol.75, pp.637-643, 2003.

M. J. Butte, V. Peña-cruz, M. Kim, G. J. Freeman, and A. H. Sharpe, Interaction of human PD-L1 and B7-1, Mol Immunol, vol.45, pp.3567-3572, 2008.

M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, vol.27, pp.111-122, 2007.

S. Yao, Y. Zhu, and G. Zhu, B7-h2 is a costimulatory ligand for CD28 in human, Immunity, vol.34, pp.729-740, 2011.

N. Poirier, G. Blancho, and B. Vanhove, A more selective costimulatory blockade of the CD28-B7 pathway, Transpl Int, vol.24, pp.2-11, 2011.

N. Poirier, G. Blancho, and B. Vanhove, CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?, Am J Transpl, vol.12, pp.1682-1690, 2012.

Y. Chen, S. Shen, B. K. Gorentla, J. Gao, and X. Zhong, Murine regulatory T Cells contain hyperproliferative and death-prone subsets with differential ICOS expression, J Immunol, vol.188, pp.1698-1707, 2012.

C. Vasu, B. S. Prabhakar, and M. J. Holterman, Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity, J Immunol, vol.173, pp.2866-2876, 2004.

S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray et al., TGFbeta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25 +regulatory cells, J Immunol, vol.176, pp.3321-3329, 2006.

R. Li, N. Perez, S. Karumuthil-melethil, B. S. Prabhakar, M. J. Holterman et al., Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25-TGF-beta 1+ adaptive regulatory T cells, J Immunol, vol.179, pp.5191-5203, 2007.

M. D. Sharma, B. Baban, and P. Chandler, Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase, J Clin Invest, vol.117, pp.2570-2582, 2007.

W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar, The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation, J Immunol, vol.181, pp.5396-5404, 2008.

S. Fu, N. Zhang, and A. C. Yopp, TGF-beta induces Foxp3 +T-regulatory cells from CD4 + CD25 -precursors, Am J Transplant, vol.4, pp.1614-1627, 2004.

M. J. Benson, K. Pino-lagos, M. Rosemblatt, and R. J. Noelle, All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation, J Exp Med, vol.204, pp.1765-1774, 2007.

K. Semple, A. Nguyen, Y. Yu, H. Wang, C. Anasetti et al., Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling, Blood, vol.117, pp.3096-3103, 2011.

P. J. Perrin, C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke, Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis, J Immunol, vol.163, pp.1704-1710, 1999.

S. P. Raychaudhuri, S. Kundu-raychaudhuri, and K. Tamura, FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model, J Invest Dermatol, vol.128, pp.1969-1976, 2008.

X. Yu, M. H. Albert, P. J. Martin, and C. Anasetti, CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens, J Clin Invest, vol.113, pp.1624-1630, 2004.

X. Z. Yu, S. J. Bidwell, P. J. Martin, and C. Anasetti, CD28-specific antibody prevents graft-versus-host disease in mice, J Immunol, vol.164, pp.4564-4568, 2000.

F. Haspot, F. Villemain, and G. Laflamme, Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses, Blood, vol.99, pp.2228-2234, 2002.

J. Li, K. Semple, and W. Suh, Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice, Biol Blood Marrow Transplant, vol.17, pp.962-969, 2011.

I. A. Laskowski, J. Pratschke, and M. J. Wilhelm, Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats, J Am Soc Nephrol, vol.13, pp.519-527, 2002.

V. M. Dong, X. Yuan, A. J. Coito, A. M. Waaga, M. H. Sayegh et al., Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection, Transplantation, vol.73, pp.1310-1317, 2002.

C. Guillonneau, C. Séveno, and A. Dugast, Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients, J Immunol, vol.179, pp.8164-8171, 2007.

H. Urakami, D. V. Ostanin, T. Hünig, and M. B. Grisham, Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation, Transplant Proc, vol.38, pp.3244-3246, 2006.

T. J. Dengler, G. Szabo, and B. Sido, Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation, Transplantation, vol.67, pp.392-398, 1999.

F. Haspot, C. Séveno, and A. Dugast, Anti-CD28 antibodyinduced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells, Am J Transplant, vol.5, pp.2339-2348, 2005.

A. Dugast, T. Haudebourg, and F. Coulon, Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion, J Immunol, vol.180, pp.7898-7906, 2008.

N. Poirier, A. M. Azimzadeh, and T. Zhang, Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation, Sci Transl Med, vol.2, pp.17-27, 2010.

B. Vanhove, G. Laflamme, and F. Coulon, Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody, Blood, vol.102, pp.564-570, 2003.

S. L. Shiao, J. M. Mcniff, T. Masunaga, K. Tamura, K. Kubo et al., Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities, Transplantation, vol.83, pp.304-313, 2007.

G. Suntharalingam, M. R. Perry, and S. Ward, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N Engl J Med, vol.355, pp.1018-1028, 2006.

P. C. Soto, L. L. Stein, N. Hurtado-ziola, S. M. Hedrick, and A. Varki, Relative over-reactivity of human versus chimpanzee lymphocytes: Implications for the human diseases associated with immune activation, J Immunol, vol.184, pp.4185-4195, 2010.

D. H. Nguyen, N. Hurtado-ziola, P. Gagneux, and A. Varki, Loss of Siglec expression on T lymphocytes during human evolution, Proc Natl Acad Sci, vol.103, pp.7765-7770, 2006.

L. Findlay, D. Eastwood, and R. Stebbings, Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412, J Immunol Methods, vol.352, pp.1-12, 2010.

R. Stebbings, L. Findlay, and C. Edwards, «Cytokine storm» in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J Immunol, vol.179, pp.3325-3331, 2007.

L. D. Shultz, F. Ishikawa, and D. L. Greiner, Humanized mice in translational biomedical research, Nat Rev Immunol, vol.7, pp.118-130, 2007.

E. J. Wagar, M. A. Cromwell, and L. D. Shultz, Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice, J Immunol, vol.165, pp.518-527, 2000.

M. King, T. Pearson, and L. D. Shultz, A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene, Clin Immunol, vol.126, pp.303-314, 2008.

D. Eastwood, L. Findlay, and S. Poole, Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells, Br J Pharmacol, vol.161, pp.512-526, 2010.

M. Tary-lehmann, P. V. Lehmann, D. Schols, M. G. Roncarolo, and A. Saxon, Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras, J Exp Med, vol.180, pp.1817-1827, 1994.

B. R. Blazar, P. A. Taylor, M. W. Boyer, A. Panoskaltsis-mortari, J. P. Allison et al., CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells, J Immunol, vol.159, pp.3460-3473, 1997.

F. Vincenti, B. Charpentier, and Y. Vanrenterghem, A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study), Am J Transplant, vol.10, pp.535-546, 2010.